Helix is led by experienced Management and Board team with excellent pharmaceutical development expertise and proven business skills. The group is committed in developing novel medicines through DOS47 and cell-based platforms.
Biochemist with expertise in protein drug development. Previous role with Sensium Technologies Inc.
Clinical operations experience with past roles at BioMS Medical, Bayer and Sanofi Synthelabo
Public company CFO with broad industry experience including senior positions with Unilever and Huhtamaki Oy
Biochemistry background; co-founder Institute of Genetic Analysis
Experienced biotech entrepreneur, pharma manager (Merck, Novartis) and life science venture capitalist in the field of oncology (Burrill & Company, Adiuvo Investments)
Founder/CEO of Alveda Pharmaceuticals, recently sold to Teligent Inc (NASDAQ), Former CEO of Bioniche Pharma Group Ltd.
Chairman/Founder Adiuvo Investments, Founder Nepentes, sold to Sanofi Aventis
Vice Rector of the Medical University of Warsaw, Corresponding Member of the Polish Academy of Science
Founder of Dominet Bank which was sold to Fortis Bank Group; President/founder of Sfinks Polska
Engineering professor, University of Toronto, Technical University of Lodz
Retired President, CEO Boehringer-Ingelheim Canada Ltd.; Senior Vice President, Corporate Partnerships and Chief Scientific Officer of Innoviva Inc.